BioSpace News Archive

Sarepta Therapeutics, Inc. today provided the following update on the Biologics License Application (BLA) for SRP-9001 (delandistrogene moxeparvovec), which is currently under review for the treatment of ambulant individuals with Duchenne muscular dystrophy (DMD) who have a confirmed mutation of the DMD gene.

GE HealthCare, a leader in precision care innovation, is announcing that its President and CEO Peter Arduini will present at the Jefferies Healthcare Conference in New York City on June 7, 2023 from 10:30 am to 10:55 am ET.

Ajax Therapeutics, Inc. today announced the appointment of Eric S. Fischer, PhD, to the Company’s Scientific Advisory Board (SAB).

Enveric Biosciences, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving its EVM201 Series.

Precision BioSciences, Inc. today announced that the Company will participate in the Stifel Genetic Medicines Day taking place May 30, 2023.

Domus Diagnostics, a U.S.-based point-of-care diagnostics company, has received an award from the National Institutes of Health to further develop its point-of-care nucleic acid amplification and detection test for simultaneous identification of COVID-19, Flu-A, Flu-B, and RSV.

Eterna Therapeutics Inc. today announced the appointment of Megan Yung as Chief Strategy Officer and General Counsel.

Mainz Biomed NV announced initial results from its colorectal cancer screening campaign through its BGM partnership with Zöeller-Kipper GmbH, part of the Zöeller group with more than 2,500 employees.

Thermo Fisher Scientific Inc. hosted its 2023 Investor Day today and provided an in-depth review of the Company’s proven growth strategy and its industry-leading businesses.

Ocugen, Inc. today announced the pricing of its underwritten public offering of 30,000,000 shares of its common stock for gross proceeds of $16.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ocugen.